MARKET

ACXP

ACXP

Acurx Pharmaceuticals Inc
NASDAQ
4.010
-0.260
-6.09%
After Hours: 3.950 -0.06 -1.50% 19:49 03/26 EDT
OPEN
4.170
PREV CLOSE
4.270
HIGH
4.250
LOW
3.940
VOLUME
159.79K
TURNOVER
--
52 WEEK HIGH
21.00
52 WEEK LOW
1.326
MARKET CAP
11.45M
P/E (TTM)
-0.7544
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACXP last week (0316-0320)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 03/19 17:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 03/16 17:05
Weekly Report: what happened at ACXP last week (0309-0313)?
Weekly Report · 03/16 10:27
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)
TipRanks · 03/14 15:50
Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners
TipRanks · 03/13 17:35
Acurx signals launch of pivotal recurrent CDI trial in H2 2026 while strengthening ibezapolstat pipeline
Seeking Alpha · 03/13 17:03
Acurx price target lowered to $10 from $20 at Alliance Global
TipRanks · 03/13 16:50
More
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Webull offers Acurx Pharmaceuticals Inc stock information, including NASDAQ: ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.